Lord, Abbett & Co
TVTX icon

Lord, Abbett & Co’s Travere Therapeutics TVTX Stock Holding History

Lord, Abbett & Co’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-135,822
Closed -$5.19M – 628
2025
Q4 		$5.19M Sell
135,822
-97
-0.1% -$3.15K 0.02% 461
2025
Q3 		$3.25M Sell
135,919
-173,311
-56% -$3.26M 0.01% 490
2025
Q2 		$4.58M Sell
309,230
-254,931
-45% -$4.23M 0.01% 467
2025
Q1 		$10.1M Buy
+564,161
New +$11.4M 0.04% 371
2015
Q4 		– Sell
-59,876
Closed -$1.21M – 947
2015
Q3 		$1.21M Sell
59,876
-104,558
-64% -$3.1M ﹤0.01% 874
2015
Q2 		$5.45M Buy
+164,434
New +$4.5M 0.01% 756

Other funds holding TVTX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Lord, Abbett & Co's TVTX Position: Q1 2026 in Review

Lord, Abbett & Co sold out of Travere Therapeutics (TVTX) in Q1 2026, closing a stake of 135,822 shares — an estimated $5.19M sold.

Lord, Abbett & Co first reported a position in TVTX in Q2 2015 and held it in 6 quarters. The position peaked at $10.1M in Q1 2025. 260 funds tracked by Wall St. Rank hold TVTX as of Q1 2026.

  • Lord, Abbett & Co reported no remaining Travere Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Lord, Abbett & Co sold 135,822 Travere Therapeutics shares in Q1 2026, an estimated $5.19M.
  • Lord, Abbett & Co first reported a position in Travere Therapeutics in Q2 2015 and held it in 6 quarters.
  • Lord, Abbett & Co's Travere Therapeutics position peaked at $10.1M in Q1 2025.
  • 260 funds tracked by Wall St. Rank held Travere Therapeutics as of Q1 2026.

Based on Lord, Abbett & Co's 13F filing for Q1 2026, filed 14 May 2026.